<div id="readability-page-1"><div><p><span>MERCK KGAA </span><span>:</span></p><ul><li>MERCK KGAA - ANNOUNCES PUBLICATION OF LONG-TERM EFFICACY AND SAFETY DATA FROM THE PHASE 3 DEFI TRIAL OF OGSIVEO® (NIROGACESTAT)</li><li>MERCK KGAA - LONG-TERM CONTINUOUS OGSIVEO TREATMENT FOR UP TO 4 YEARS WAS ASSOCIATED WITH FURTHER TUMOR SIZE REDUCTIONS,  INCREASE IN OBJECTIVE RESPONSE RATE</li><li>MERCK KGAA - SUSTAINED IMPROVEMENT IN DESMOID TUMOR SYMPTOMS AND CONSISTENT SAFETY PROFILE</li></ul></div></div>

MKKGY

<p>MERCK KGAA :MERCK KGAA - ANNOUNCES PUBLICATION OF LONG-TERM EFFICACY AND SAFETY DATA FROM THE PHASE 3 DEFI TRIAL OF OGSIVEO® (NIROGACESTAT) MERCK KGAA - LONG-TERM CONTINUOUS OGSIVEO TREATMENT FOR UP TO 4 YEARS WAS ASSOCIATED WITH FURTHER TUMOR SIZE REDUCTIONS, INCREASE IN OBJECTIVE RESPONSE RATEMERCK KGAA - SUSTAINED IMPROVEMENT IN DESMOID TUMOR SYMPTOMS AND CONSISTENT SAFETY PROFILE</p>

Merck Publishes Long-Term Efficacy And Safety Data From Phase 3 Defi Trial Of Ogsiveo®